Stock screener

FATE

Conviction 82HealthcareScan · Thu, Jun 25, 2026
FATE$1.85-10.19%
ResistanceSupportVol 14Insider sell
63 bars
2
Vol MA14 3.9M
Mar 26Apr 14May 1May 19Jun 8Jun 25
FATE THERAPEUTICS INCBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.fatetherapeutics.com
Price1.85
Change-10.19%
Gap+0.97%
Rel volume2.64×
Avg volume4.39M
Avg $ vol9.71M
SMA 202.15
SMA 501.93
SMA 2001.37
Price vs 50-3.99%
Price vs 200+34.75%
MA stackmixed
50/200 cross
Supertrenddown · 2.59
RSI (14)44
MACD hist-0.03
MACD cross
Stoch %K / %D7 / 33
ADX (14)13
+DI / −DI22 / 22
RSI divergence
MACD divergence
ATR %+12.49%
ADR %10.78%
52w high2.84
52w low0.9214
From 52w high-34.86%
Above 52w low+100.78%
New 52w highNo
SqueezeOff
Bollinger width54.57%
%B0.24
Donchian pos3.29%
Donchian high2.88
Donchian low1.82
AVWAP (52w high)2.20
vs AVWAP high-15.92%
AVWAP (52w low)1.55
vs AVWAP low+19.31%
OBV trendFlat
Chaikin MF (20)-0.14
Today vs 20d2.64×
Avg vol (14d)3.9M
Avg vol (20d)4.39M
Avg $ vol (20d)9.71M
Market cap215.63M
RS 3m (vs SPY)+70.04%
RS 6m (vs SPY)+88.45%
RS line new highNo
Trend template6/8
Technical rank62.9
1 week-5.61%
1 month-13.95%
3 months+51.64%
6 months+76.19%
1 year+58.12%
YTD+87.55%
P/E-1.58
P/B1.20
P/S32.45
P/FCF-1.92
EPS-1.15
Div yield
ROE-75.85%
ROA-47.84%
Debt/Eq0.13
Current5.85
EV/EBITDA-1.48
Gross margin
Net margin
Rev growth-51.24%
EPS growth26.82%
Price target5.24
Target upside183.24%
Analyst ratingBuy
Institutional72.70%
Ent. value199.47M
Revenue1.3M
Net income-31.21M
Gross profit
Free cash flow-112.04M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out
Employees161
ListedTue, Oct 1, 2013
Free float98.83M
Float %85.0%
Short interest10.7M
Days to cover2.1d
Short volume40.7%
Squeeze score47 / 100
Next earnings
EPS forecast
Last EPS vs est−$0.26 vs −$0.29
Last surprise+10.3% beat
Setup gradeA
Conviction82 / 100
Pattern quality
Tech rank62.9 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction
Pattern family
Resistance2.67
Support1.71
Days since event
Candle confirm
News sentiment

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in FATE

All disclosures →
No recent disclosed trades by Congress in FATE. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in FATE · 5 buys · 4 sells

InsiderSideShares
Valamehr Bahram
President and CEO · Common Stock · 2026-05-20
Sell28.95K
TAHL CINDY
See Remarks · Common Stock · 2026-05-20
Sell25.59K
TAHL CINDY
See Remarks · Common Stock · 2026-05-06
Exercise122.22K
TAHL CINDY
See Remarks · Stock Option (Right to Buy) · 2026-05-06
Exercise44.44K
TAHL CINDY
See Remarks · Stock Option (Right to Buy) · 2026-05-06
Exercise122.22K
TAHL CINDY
See Remarks · Common Stock · 2026-05-06
Exercise44.44K
EPSTEIN ROBERT S
Director · Stock Option (Right to Buy) · 2026-05-05
Exercise25K
RASTETTER WILLIAM H
Director · Common Stock · 2026-05-05
Other
RASTETTER WILLIAM H
Director · Common Stock · 2026-05-05
Exercise25K
RASTETTER WILLIAM H
Director · Stock Option (Right to Buy) · 2026-05-05
Exercise25K

SEC filings

EDGAR filings in FATE · 2 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.